Form 8-K - Current report:
SEC Accession No. 0001193125-24-260923
Filing Date
2024-11-18
Accepted
2024-11-18 16:11:03
Documents
15
Period of Report
2024-11-18
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d840591d8k.htm   iXBRL 8-K 55307
2 EX-99.1 d840591dex991.htm EX-99.1 36601
  Complete submission text file 0001193125-24-260923.txt   268673

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nams-20241118.xsd EX-101.SCH 3569
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nams-20241118_def.xml EX-101.DEF 14184
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE nams-20241118_lab.xml EX-101.LAB 23100
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nams-20241118_pre.xml EX-101.PRE 15032
17 EXTRACTED XBRL INSTANCE DOCUMENT d840591d8k_htm.xml XML 5851
Mailing Address GOOIMEER 2-35 NARRDEN P7 1411 DC
Business Address GOOIMEER 2-35 NARRDEN P7 1411 DC 35 206 2971
NewAmsterdam Pharma Co N.V. (Filer) CIK: 0001936258 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41562 | Film No.: 241471579
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)